AVIR logo

Atea Pharmaceuticals Inc. (AVIR)

$3.96

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AVIR

Market cap

$318004414

EPS

-1.95

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.763147

Price on AVIR

Previous close

$4.12

Today's open

$4.11

Day's range

$3.85 - $4.18

52 week range

$2.92 - $6.45

Profile about AVIR

CEO

Jean-Pierre Sommadossi

Employees

55

Headquarters

Boston, MA

Exchange

Nasdaq Global Select

Shares outstanding

80304145

Issue type

Common Stock

AVIR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on AVIR

Atea Pharmaceuticals: A Clean DDI Profile And Shorter Treatment Duration Threaten Current Market Leaders

Atea Pharmaceuticals is a Buy: positive Phase 3 HCV data and a runway into mid-2028 support a steep discount to estimated value. BEM/RZR achieved a 94% cure rate versus Epclusa's 95%, with an eight-week regimen and clean drug-interaction profile supporting differentiation. C-FORWARD data in early 2027 are the critical catalyst; success could support a mid-2027 NDA, while failure could derail submission and increase dilution.

news source

Seeking Alpha • Nov 13, 2026

news preview

Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

What Atea Pharmaceuticals (AVIR) Said on Its Q3 Earnings Call

Atea Pharmaceuticals NASDAQ: AVIR is targeting a mid-2027 U.S. application for its hepatitis C treatment, pending results from a second late-stage trial, and has secured a credit facility of up to $200 million to support its development and commercial plans.

news source

MarketBeat • Nov 10, 2026

news preview

Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection

news source

GlobeNewsWire • Nov 9, 2026

news preview

Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital

BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $200 million. The facility strengthens Atea's financial position and provides strategic and operational flexibility as the Company expands its commercial-related activities in anticipation of the product launch of the regimen of bemnifosbuvir/ruzasvir (BEM/RZR) in the United States (US) for the treatment of chronic hepatitis C virus (HCV), if approved, and advances the Company's clinical program for hepatitis E virus (HEV).

news source

GlobeNewsWire • Nov 9, 2026

news preview

Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2026, and to provide a business update.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 15, 2026

news preview

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 12:20 p.m.

news source

GlobeNewsWire • Sep 8, 2026

news preview

Atea Pharmaceuticals Q2 Earnings Call Highlights

Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, marketed as Epclusa.

news source

MarketBeat • Aug 12, 2026

news preview

Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 13, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Atea Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Atea Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AVIR on M1